Quantcast

Latest Actavis Stories

2014-10-23 08:35:32

DUBLIN, Oct. 23, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals, Inc. and Amneal Pharmaceuticals' Abbreviated New Drug Applications (ANDAs) for generic versions of Actavis' Lo Loestrin® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol...

2014-10-22 08:32:25

-- Relamorelin is a Novel Peptide Ghrelin Agonist for Diabetic Gastroparesis -- DUBLIN and BOSTON, Oct. 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced that Actavis has been granted an exclusive option to acquire Rhythm's wholly owned subsidiary, Rhythm Health, Inc., which is developing relamorelin (RM-131), a peptide ghrelin agonist, for the treatment of diabetic...

2014-10-16 08:31:22

DUBLIN, Oct. 16, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Methylphenidate Hydrochloride for Extended-release Oral Suspension, 5 mg/mL. Actavis' ANDA product is a generic version of Pfizer and Tris Pharma's Quillivant XR(®), which is a central nervous system stimulant indicated for the treatment of Attention Deficit...

2014-10-15 04:22:14

TAINAN, Oct. 15, 2014 /PRNewswire/ -- ScinoPharm (TWSE:1789) announced that it was named the "Active Pharmaceutical Ingredient (API) Supplier of the Year" at the Global Generics and Biosimilars Awards co-hosted by Generics bulletin and Ark Patent Intelligence. The award recognizes excellent performance across a range of business activities and was won in strong competition against a number of leading Pharmaceutical companies including Dr. Reddy's, Teva, Perrigo, Unichem, etc. The...

2014-10-14 12:30:51

BOSTON, Oct. 14, 2014 /PRNewswire/ -- The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on October 28(th), 2014, to discuss financial results for the third quarter ended September 30, 2014. The call details are as follows: Date: Tuesday, October 28, 2014 Time: 8:30 AM EDT Dial-in Toll free: (866) 374-4635 (U.S.), (855) 669-9657 numbers: (Canada) or, International:...

2014-10-06 08:28:37

- Lead Product DALVANCE(TM) a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings - DUBLIN, Ireland and CHICAGO, Oct. 6, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Durata Therapeutics, Inc. (NASDAQ: DRTX), an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses, today announced that they...

2014-09-30 08:32:22

Trelstar® one-, three-, and six-month dosing options now available TORONTO and LAUSANNE, Switzerland, September 30, 2014 /PRNewswire/ -- Trelstar(R) (triptorelin pamoate), indicated in Canada for the palliative treatment of hormone dependent advanced prostate cancer,[1] is now available in a six-month dosing option (22.5 mg). The new dosing option eases the burden on patients, with a decreased number of injections and a low incidence of injection site pain, while providing...

2014-09-30 08:32:14

DUBLIN, Sept. 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it intends to release third quarter 2014 financial results on Wednesday, November 5, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:00 a.m. Eastern Standard Time on Wednesday, November 5, 2014 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the...

2014-09-26 00:21:14

IRVINE, Calif., Sept. 25, 2014 /PRNewswire/ -- Pentwater Capital Management today issued the following letter to the Board of Directors of Allergan, Inc.: September 25, 2014 Mr. David E. I. PyottMr. Michael R. Gallagher Mr. Russell T. Ray Dr. Trevor Mervyn Jones Mr. Louis J. Lavigne Dr. Deborah Dunsire Dr. Peter J. McDonnell Mr. Timothy D. Proctor Mr. Henri A. Termeer 2525 Dupont DriveIrvine, CA 92612 Dear Members of the Board of Directors: Pentwater Capital Management is the...

2014-09-25 16:26:46

DUBLIN, Sept. 25, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Transdermal System, 5 mcg/hr, 10 mcg/hr and 20 mcg/hr. Actavis' ANDA product is a generic version of Purdue Pharma's Butrans(®), which is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related